The SNP rs7903146 at the transcription factor 7-like 2 (TCF7L2) locus is established as the strongest known genetic marker for type 2 diabetes via genome-wide association studies. However, the functional SNPs regulating TCF7L2 expression remain unclear. Here, we show that the SNP rs7074440 is a candidate functional SNP highly linked with rs7903146. A reporter plasmid with rs7074440 normal allele sequence exhibited 15-fold higher luciferase activity compared with risk allele sequence in hepatocytes, demonstrating a strong enhancer activity at rs7074440. Additionally, we identified C-FOS as an activator binding to the rs7074440 enhancer using a TFEL genome-wide screen method. Consistently, knockdown of C-FOS significantly reduced TCF7L2 expression in hepatocytes. Collectively, a novel enhancer regulating TCF7L2 expression was revealed through searching for functional SNPs.
The SNP rs7903146 at the transcription factor 7-like 2 (TCF7L2) locus is established as the strongest known genetic marker for type 2 diabetes via genome-wide association studies. However, the functional SNPs regulating TCF7L2 expression remain unclear. Here, we show that the SNP rs7074440 is a candidate functional SNP highly linked with rs7903146. A reporter plasmid with rs7074440 normal allele sequence exhibited 15-fold higher luciferase activity compared with risk allele sequence in hepatocytes, demonstrating a strong enhancer activity at rs7074440. Additionally, we identified C-FOS as an activator binding to the rs7074440 enhancer using a TFEL genome-wide screen method. Consistently, knockdown of C-FOS significantly reduced TCF7L2 expression in hepatocytes. Collectively, a novel enhancer regulating TCF7L2 expression was revealed through searching for functional SNPs.
Keywords: enhancer; functional SNP; transcription factor; type 2 diabetes Type 2 diabetes is a complex human disease caused by both genetic and environmental factors [1] . Approximately 10 years ago, a number of genetic variants associated with type 2 diabetes were identified by genome-wide association studies (GWAS) [2] [3] [4] . Among these genomic variants, the TCF7L2 polymorphisms, first reported by Grant et al. [5] using microsatellite markers, have been reproducibly documented to be the most strongly associated markers of type 2 diabetes risk by numerous investigations among different ethnic groups, and the SNP rs7903146 has been established as the representative genetic marker [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] .
Transcription factor 7-like 2 (TCF7L2) is located on chromosome 10, and encodes a high mobility group (HMG) box-containing transcription factor [16] . It participates in the Wnt-signaling pathway and activates transcription from promoters with several copies of the TCF motif.
Regarding the mechanistic link between TCF7L2 polymorphisms and the etiology of type 2 diabetes, many studies have focused on the pancreatic beta cell, because early indications were that individuals with variants of TCF7L2 associated with increased risk for type 2 diabetes exhibit impaired insulin secretion [6, 7] . However, several studies have indicated that TCF7L2 polymorphisms are also associated with elevated rates of hepatic glucose production and reduced hepatic insulin sensitivity in humans in vivo [9, 17, 18] . Thus, the TCF7L2 risk SNPs may affect the metabolic functions of both pancreatic islets and the liver [19] [20] [21] .
Abbreviations GWAS, genome-wide association study; SNP, single-nucleotide polymorphisms; TCF7L2, transcription factor 7-like 2; TFEL, transcription factor expression library.
To date, all recognized type 2 diabetes-related TCF7L2 risk SNPs are located within intronic regions of this gene [16] . Because these SNPs do not affect the coding sequence, one may assume that they affect expression of TCF7L2. However, the underlying mechanism for such transcriptional regulation currently remains unclear.
Recently, we have independently developed a useful library for pairing an enhancer and its transactivator [22] . By utilizing this method named TFEL scan, it became possible to easily determine the correspondence between an enhancer and its transactivator.
These situations prompted us to search for a functional enhancer variant within the TCF7L2 gene, to identify the corresponding transcription factor(s) for this enhancer, and to elucidate the molecular mechanisms determining the genetic variation of TCF7L2 expression. For this purpose, we searched for the functional SNPs highly linked with the GWAS lead SNP rs7903146 with enhancer activities as a clue and identified the corresponding transactivator using TFEL scan.
Materials and methods

Search for candidate functional SNPs
Several SNP annotation databases were used to identify possible SNP functions. The UCSC genome browser (https://ge nome.ucsc.edu/) was used as the source of genome-wide maps of the chromatin state of the region of interest of the gene. The SNP rs7903146 has been identified to be the most strongly associated with type 2 diabetes by GWAS [4, 23] . The SNP rs7903146 is a 'marker' SNP and candidate functional SNPs highly linked with rs7903146 were selected with HaploReg V4 (http://compbio.mit.edu/HaploReg) [24] , using a linkage disequilibrium (LD) threshold of r 2 ≥ 0.60 with rs7903146 at two or more areas among Europe, America, and Asia and a minor allele frequency (MAF) threshold of freq > 0 in all the areas. As a result, 21 SNPs including rs7903146 were selected as candidate functional SNPs. All the SNPs are located approximately within 67-kb region extending from 112 989 975 to 113 057 250 on chromosome 10 (UCSC Genome Browser hg38).
Construction of luciferase reporter plasmids
The fragment of one or three tandem copies of the each SNP 25-bp region which containing 'risk allele' was cloned into BamHI and SalI sites located at the 3 0 end of firefly luciferase reporter gene of pGL3 promoter plasmid (Promega Corporation, Madison, WI, USA) (SV40pro-Firefly Luc-SNPx1 and SV40pro-Firefly Luc-SNPx3). Similarly, the fragments containing 'normal allele' were cloned into BamHI and SalI sites located at the 3 0 end of renilla luciferase reporter gene of a modified pGL3 promoter plasmid whose firefly luciferase reporter gene was substituted by renilla luciferase reporter gene (SV40pro-Renilla LucSNPx3). These fragment sequences are described in Table S1 . The luciferase activity in transfectant was measured on a luminometer as described previously [25] .
In vivo imaging of enhancer activity
Six-week-old ICR male mice were purchased from SLC (Shizuoka, Japan). All animals were maintained in a temperature-controlled environment with a 14 h-light/10 hdark cycle and were given free access to standard laboratory diet and water. All animals studied were anesthetized and euthanized according to the protocol approved by the Tsukuba University Animal Care and Use Committee. The fragments containing three tandem rs7074440 25-bp region of normal allele or risk allele SNP sequence with SV40 promoter region linked to luciferase reporter gene cut from SV40pro-Firefly Luc-SNPx3 were inserted into the Gateway entry vector pENTR4 (Invitrogen, Carlsbad, CA, USA), and the adenoviral plasmid was generated by homologous recombination between the entry vector and the pAd promoterless vector (Invitrogen) (Ad-SV40pro-Firefly LucSNPx3). After the transfection of the plasmid into 293A cells, recombinant adenoviruses were collected by CsCl gradient centrifugation as described previously [26] .
In vivo imaging was performed as described previously [22] . Adenoviruses were injected intravenously into ICR male mice at the dose of 1 9 10 8 P.F.U./body. After 3 days, mice were anesthetized and luciferin dissolved in PBS (7.5 mgÁmL
À1
) was injected into the intraperitoneal cavity. The luminescence in the liver was visualized using an In Vivo Imaging System (IVIS TM , Xenogen, Alameda, CA, USA). For the luminescence quantification, tissue samples (about 50 mg) were homogenized with a Polytron in 300 lL of Reporter Lysis Buffer (Promega Corporation) and centrifuged at 25 000 g for 15 min, and luciferase activity in the supernatant was measured on luminometer. To determine hepatic transduction efficiency, the pellets obtained in the process described above were digested with proteinase K and the DNA samples were extracted with phenol/chloroform and ethanol precipitation, and then the amounts of adenoviral DNA in the samples were quantified using Q-RT PCR method as described previously [27] . The primers used for the quantification of luciferase gene were 5 0 -GTCCGGTTATGTAAACAATCC-3 0 and 5 0 -ATGAA-
Genome-wide transcription factor screening HEK 293 cells in a 48-well plate were co-transfected with the TFEL clones [22] and reporter plasmids of SV40pro-Renilla Luc-SNPx3 plus SV40pro-Firefly Luc-SNPx3. Cells were lysed in Reporter Lysis Buffer (Promega Corporation) 24 hr after transfection, and then firefly and renilla luciferase activities were measured.
Electrophoretic mobility shift assay Quick Master Mix (Promega Corporation), 0.2 lL of 1 mM methionine, and PCR-amplified DNA (0.1 lg) described above were mixed and incubated at 37°C for 90 min. Electrophoretic mobility shift assay (EMSA) was performed as previously described [28] . Briefly, three DNA probes were prepared by annealing two oligonucleotides. The probe sequences are listed in 
Chromatin immunoprecipitation assays
Nuclear extracts was prepared from HepG2 cell line. Chromatin immunoprecipitation (ChIP) assays were performed as described previously [28, 29] . Antibodies used for the ChIP assay were anti-c-Fos antibody (sc-52-G) and normal goat IgG (sc-2061). DNA quantity was measured using real-time PCR. 1% of the input genomic DNA was used for input genomic c-DNA. Primers used to amplify TCF7L2 gene Locus containing SNP rs7074440 region were as follows: (125 bp Twenty-four hours after transfection, cells were lysed and then western blotting was performed using anti-FLAG (F3165) (mouse monoclonal) antibody (Sigma-Aldrich, Zwijndrecht, Netherlands) as described previously [22] . Both C-FOSi-1 and C-FOSi-2 effectively knocked down the c-Fos protein expression (data not shown). Adenovirus vectors for knockdown were generated by homologous recombination between the entry vector and the pAd promoterless vector (Ad-C-FOSi-1 and Ad-C-FOSi-2) using the Gateway system. LacZ-specific shRNA expression plasmids (LacZi) and adenovirus vector (Ad-LacZi) were described previously [26] .
RNA interference
RNA isolation and quantitative reverse transcription PCR
Total RNA was extracted from HepG2 cells with Sepazol reagent (Nacalai Tesque, Kyoto, Japan) and transcribed into cDNA using reverse transcription reagent kit (TOYOBO, Osaka, Japan). Quantitative reverse transcription PCR was performed using ABI 7500 System (Applied Biosystems Ò 7500
Fast, Applied Biosystems, Framingham, MA, USA). Q-RT PCR was performed using SYBR Green PCR master mix. The primer sets were as follows: human C-FOS, 
Statistical analyses
Data are expressed as means AE SEM. Differences between two groups were assessed using an unpaired two-tailed Student's t-test. Data sets involving more than two groups were assessed by ANOVA using STATCEL3 Software (OMS Publishing Inc., Saitama, Japan). The differences were considered statistically significant at P < 0.05.
Results
Selection of potential functional SNPs
The SNP rs7903146 has been identified to be the most strongly associated marker of type 2 diabetes by GWAS [2] and is located in intron 4 of the TCF7L2 gene. In order to identify potential functional SNPs linked with rs7903146, we selected 21 candidate SNPs with a strong linkage disequilibrium to rs7903146 (r 2 ≥ 0.60) including itself (Fig. 1A) . The details of SNPs selection criteria were described in 'Materials and Methods'. Of 21 candidate SNPs, 9 SNPs are located within 10 kb upstream of rs7903146 locus and other 11 SNPs are located within 60 kb downstream of that. All SNPs are located within intron 4 of the TCF7L2 gene (Fig. 1B) .
Functional assessment of TCF7L2 SNPs shows enhancer activity at rs7074440
To examine which of these 21 SNP candidates are functional SNPs affecting TCF7L2 gene expression in human hepatocytes, we performed a luciferase reporter assay in human hepatoma cell lines HepG2 and Huh7. To this end, we constructed reporter plasmid containing three copies of 25-bp region surrounding each SNP from 'normal' allele placed at the 3 0 end of renilla luciferase reporter gene and those from 'risk' allele placed at the 3 0 end of firefly luciferase reporter gene (SV40pro-Renilla Luc-SNPx3 and SV40pro-Firefly Luc-SNPx3, respectively) to assess enhancer activity of the sequence around each SNP (Fig. 1C) . Next, we co-transfected the two plasmids for each SNP as a pair of normal and risk into HepG2 and Huh7 hepatocytes. As shown in Fig. 1D , the normal allele reporter plasmid for rs7074440 exhibited significantly higher luciferase activity compared with risk allele reporter plasmid in both HepG2 and Huh7 cell lines. In contrast, in nonhepatic cell lines HEK 293 and HeLa cells, significant allele-specific differences for any SNP plasmids were not observed (Fig. S1 ). To further compare the normal and risk alleles around rs7074440 in the same reporter background, two plasmids based on firefly luciferase reporter (SV40pro-Firefly Lucrs7074440x3) were constructed and transfected individually in HepG2 cells. As shown in Fig. 2A , SV40pro-Firefly Luc-rs7074440x3 for normal (G) allele exhibited 15-fold higher luciferase activity compared with that for risk (A) allele, demonstrating a strong enhancer activity of normal (G) allele at rs7074440. The reporter plasmid containing 'one' copy of the 25-bp region surrounding rs7074440 from normal allele also showed significantly higher luciferase activity compared with that from risk allele reporter plasmid (SV40pro-Firefly Luc-rs7074440x1) in HepG2 cells (Fig. S2) . Consistently, a similar result was obtained about reporter plasmids driven by TCF7L2 gene promoter (TCF7L2 pro-Firefly Luc-rs7074440x1) in HepG2 cells (Fig. 2B) . The results in Fig. 2A ,B also indicate that rs7074440 risk (A) allele has no enhancer activity in HepG2 cells.
To further evaluate the rs7074440 enhancer activity in hepatocytes in the in vivo setting, we performed animal experiments using the in vivo Ad-luc analytical system originally developed by ourselves [22] . Adenoviruses containing SV40 promoter and reporter gene plus three copies of rs7074440 SNP region from normal and risk allele (Ad-SV40pro-Luc-rs7074440x3) were transduced in the mouse livers. The quantification results of luciferase activities using both in vivo imaging system and liver homogenized sample demonstrated that the enhancer activity of normal (G) allele was significantly increased compared with risk (A) allele in the liver (Fig. 2C) . These results further confirmed that rs7074440 normal (G) allele has a strong enhancer activity in hepatocytes.
TFEL genome-wide screen of trans-acting factors for rs7074440 identifies c-Fos
To identify transcription factors that can bind to rs7074440 and potentially regulate the expression of TCF7L2, we screened 1588 genome-wide transcription factors from the Transcription Factor Expression Library (TFEL), our original library that is composed of nearly all the transcription factors in the mouse genome [22] . As a result of TFEL scan, c-Fos transcription factor was identified as an activating factor, because c-Fos exhibited higher transcription activity against the normal (G) allele reporter plasmid compared with the risk (A) allele (Fig. 3A) . To investigate strictly the transcriptional effect of c-Fos on SNP rs7074440 region, we performed luciferase assays with the same reporter of normal (G) and risk (A) allele (SV40pro-Luc-rs7074440x3) co-transfected with c-Fos expression plasmid in HEK 293 cells. Consistent with the screening experiment, luciferase activity of normal (G) allele construct was significantly increased by c-Fos but that of risk (A) allele was not changed (Fig. 3B ).
C-FOS directly binds to rs7074440
Next, to assess how the variations of the SNP alter protein-DNA binding, we performed EMSA using a 
SV40pro-Firefly Luc-SNPx3
Firefly Luc radiolabeled DNA probe of rs7074440 region and c-Fos and c-Jun protein synthesized by in vitro translation system. Figure 4A showed that a radiolabeled DNA probe containing the normal (G) allele of rs7074440 more strongly bound to c-Fos and c-Jun heterodimer (AP-1) protein complex compared with the risk (A) allele. Furthermore, the chromatin immunoprecipitation analysis to confirm the endogenous binding of C-FOS proteins to the rs7074440 loci in vivo revealed that C-FOS protein actually bound to the rs7074440 within TCF7L2 gene in HepG2 cells (Fig. 4B) . We also ascertained that HepG2 and Huh7 genome have rs7074440 normal allele (data not shown).
SV40-Pro
To obtain further evidence that C-FOS binds to rs7074440, we searched using the ENCODE data on the UCSC Genome Browser. As shown in Fig. S3 , the transcription factor ChIP-seq data from ENCODE project (UCSC Genome Browser on Human Feb. 2009 (GRCh37/hg19) Assembly) demonstrates that rs7074440 is overlapped with the peak indicating FOS transcription factor binding site.
These lines of evidence indicate that C-FOS directly binds to rs7074440 normal (G) allele and that the risk (A) allele mutation attenuates its binding.
Knockdown of C-FOS decreases TCF7L2 gene expression
To clarify the role of C-FOS in the regulation of TCF7L2 gene expression in hepatic cells, we examined SV40pro-Luc-rs7074440x3
TCF7L2 pro-Firefly Luc-rs7074440x1
Normal ( the effect of C-FOS knockdown using adenoviruses in HepG2 and Huh7, whose genomes we conformed had rs7074440 normal (G) allele (data not shown). As shown in Fig. 5A ,B, the shRNA adenoviruses targeting C-FOS (Ad-C-FOSi-1 and Ad-C-FOSi-2) significantly decreased TCF7L2 mRNA levels. These data suggest that C-FOS can regulate TCF7L2 expression via its binding to rs7074440 normal (G) allele in hepatic cell lines.
Discussion
In the present study, we demonstrated that the SNP rs7074440 is a candidate functional SNP altering TCF7L2 gene expression through interaction with a transcription factor C-FOS in hepatocytes. We searched for the functional SNPs highly linked with the GWAS lead SNP rs7903146 known as a susceptibility marker of type 2 diabetes in the liver because the data pointing at the liver are scarce compared with pancreatic beta cells, and successfully identified rs7074440 as a potential candidate of causal SNP as well as a novel enhancer controlling TCF7L2 gene expression in hepatocytes. The SNP rs7074440 is one of the several dozen SNPs within the intron 4 of TCF7L2 gene (Fig. 1B) As previous reports investigating the relationship between SNPs and their enhancer activities at the TCF7L2 locus, the lead SNP rs7903146 itself has been shown to affect gene expression in a mouse pancreatic MIN6 cell line [30, 31] . However, in this study, we did not found that the SNP rs7903146 has any enhancer activity in hepatic cell lines (Fig. 1D) , suggesting that the involvement of rs7903146 is limited to pancreatic beta cells. Another SNP rs4132670 has also been reported to exhibit 1.3-fold higher levels of enhancer activity in the Huh7 cell line [32] , although this tendency was not observed in our study.
There are opposing views on the role of TCF7L2 in the regulation of glucose metabolism in the liver and in the pathogenesis of type 2 diabetes. In some literatures, it is considered that lower expression of TCF7L2 is preferable. For example, Boj et al. [19] reported that liver-specific Tcf7 l2 knockout mice showed reduced hepatic glucose production during fasting and displayed improved glucose homeostasis when maintained on high-fat diet. In contrast, Norton et al. reported that silencing of TCF7L2 induced a marked increase in hepatic glucose output, which was accompanied by significant increases in the expression of the gluconeogenic genes, while the overexpression of TCF7L2 reversed this phenotype and significantly reduced hepatic glucose output [33] . This tendency was reproduced by Oh et al. [20] , where they showed that knockdown of hepatic TCF7L2 promoted increased blood glucose levels and glucose intolerance with increased gluconeogenic gene expression. Conversely, overexpression of a nuclear isoform of TCF7L2 in high-fat diet-fed mice ameliorated hyperglycemia with improved glucose tolerance. Ip et al. [21] also demonstrated that TCF7L2 serves a beneficial role in suppressing hepatic gluconeogenesis using a liver-specific dominant-negative TCF7L2 transgenic mouse model. These reports are consistent with our results that the risk allele mutation lowers TCF7L2 expression in hepatocytes, although we do not have any evidence for the functional role of the SNP.
After we identified rs7074440 as a novel enhancer controlling TCF7L2 gene expression, we found the corresponding transactivator using TFEL scan. TFEL is a plasmid library we independently developed in order to pair an enhancer and its transactivator [22] , which enabled us to easily determine the correspondence between an enhancer and its transactivator. In the present study, we applied this method to find correspondence between SNPs and transcription factors and succeeded in identifying C-FOS transcription factor, establishing a new method of 'TFEL SNP scan'. 
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